|
|
|
|
IQ 577® Laser System – True yellow laser for retinal disorders.
NEW - MicroPulse® Laser Therapy for Fovea-Friendly™* laser grids and tissue-sparing* combo therapies.
PRODUCT HIGHLIGHTS
- High transmission through dense ocular media
- Dual Port for efficient setup of alternate delivery devices
- Repeatable macular and foveal laser sessions
- Maximize workflow efficiency Learn How
|
Schedule a hands-on demo Schedule a no-obligation demo to see for yourself how MicroPulse Technology and IRIDEX’s Family of Products can take YOUR practice to the next level.
|
True Yellow, 577nm wavelength for precise performance - High transmission through dense ocular media
- Consistent laser lesions for fast procedure time
- Low power required for increased patient comfort
Intelligent and intuitive design - Dual Port for efficient setup of alternate delivery devices
- Intuitive graphic touch screen interface for ease of use
- Programmable memory presets for multiple users
Optional Module for MicroPulse Laser Therapy - Repeatable macular and foveal laser sessions
- Success with refractory and sub-clincal edema
Wavelength |
577 nm Yellow |
Weight |
19.2 lb (9.0 kg) |
Dimensions |
8.5" H x 12" W x 14" D
(21 cm x 30 cm x 35 cm) |
Connector Type
|
RFID | Resistor |
Electrical |
100-240 VAC, 50/60 Hz
|
Cooling |
Whisper fan |
Exposure Duration |
CW-Pulse: 10-3000 ms |
Exposure Interval |
CW-Pulse: 10-3000 ms |
MicroPulse Duration |
MicroPulse: 0.05-1.00 ms |
MicroPulse Interval |
MicroPulse: 1.00-10.00 ms |
Aiming Laser |
Diode laser, 635 nm nominal |
Delivery Device Power Output |
Portable SLA: 0-2000 mW
LIO: 0-2000 mW
EndoProbe: 0-2000 mW |
|
|
IQ 577 Laser Video
|
|
|
Tratamiento de Retina con el Laser IQ 577
|
|
|
Testimonial Dr Sergio Rojas
|
|
|
MicroPulse for when injections are not enough - Dr. Marco Zarbin
|
|
|
Successful MicroPulse Treatment for Macular Edema in Retinal Vein Occlusion
|
|
|
IRIDEX MicroPulse ESCRS 2018 Symposium Q&A
|
|
|
IRIDEX at the American Academy of Ophthalmology 2018
|
|
|
Tratamiento Para la Retina con Láser MicroPulse de IRIDEX - Dr. Munir Escaf
|
|
|
The Role of Laser Therapy in the Treatment of Retinal Diseases
|
|
|
Long-term follow-up of 577 nm micropulse laser for central serous chorioretinopathy - Dr. Andre Maia
|
|
|
IQ 577
|
Optional Accessories
Full-Featured Remote Control
- Compact design for easy placement or use in sterile field
- View displays and adjust parameters from two vantage points for increased convenience and efficiency
Wireless Footswitch
- No cord, no clutter, no limitations
- Allows precise physician control over power settings
- Available with power-adjust to control laser actuation and power settings
Munir Escaf, MD Retina Specialist Clinica Carriazo Barranquilla Atlantico, Columbia | | Jonathan Feistman, MD Retina Specialist NYC Retina New York City, NY | | Brian Horsman, MD Director, Retina Group Barnet Dulaney Perkins Eye Center Phoenix, AZ USA | | Brandon Johnson, MD NYC Retina New York, NY USA | | Ahad Mahootchi, MD Medical Director The Eye Clinic of Florida Zephyrhills, FL | | Walid Mangal, DO Florida Vision Institute Stuart, FL USA | | "By incorporating MicroPulse, my injection burden decreases by one-third at a minimum, which is a conservative estimate. The versatility of MicroPulse to treat retinal disorders and glaucoma allows me to provide my patients with a treatment that’s clinically effective, cost effective, and time effective.""MLT is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications." Jason Friedrichs, MD, MS Friedrichs Eye Sycamore, IL USA | "The MicroPulse P3 Device has become an essential part of my armamentarium for use in glaucoma surgical procedures. It provides a very safe and efficacious solution for IOP control. I have used MicroPulse P3 for some of my most complicated cases but also I feel comfortable enough using it for patients with earlier disease in which we want to avoid a filtering bleb or the placement of hardware in the eye." Robert Noecker, MD, MBA Ophthalmic Consultants of Connecticut Fairfield, CT USA | "I have found the MicroPulse P3 Device to be a non-incisional, easy, and safe way to reduce pressure anytime my patients need it, and it is predictable and highly efficacious." Melissa Toyos, MD Toyos Clinic Nashville, TN USA | "MLT is both safe and durable. This therapy can be considered a first-line treatment for glaucoma patients, as well as patients who haven’t seen significant effects from medications." Ike Ahmed, MD, FRCSC Prism Eye Institute Toronto, Ontario, Canada | "I have been impressed that the MicroPulse P3 therapy with the Cyclo G6 Glaucoma Laser can deliver pressure lowering in a broad range of glaucomas, including mild and moderate patients who I want to free from the adverse effects of drops." Rolando Toyos, MD Toyos Clinic Nashville, TN USA | "The visualization of the ciliary body and the surrounding area is impressive. It has really helped me to deliver a patient-specific, targeted CPC treatment with an easy-to-use probe." Steven Vold, MD Vold Vision Fayetteville, AR USA | "You can really consider TSCPC in almost all glaucoma situation, even malignant glaucoma. It is not just relegated to end-stage treatment anymore." Dr. Jeffrey Kammer Vanderbilt Eye Institute Nashville, TN | "TSCPC is a surgery that can be done before or after any other surgery. It is very versatile from that standpoint. " Nathan Radcliffe, MD New York Eye Surgery Center Bronx, NY USA | "Recovery with TSCPC is much more rapid and the postoperative care much less involved than with someone who has had an incisional glaucoma case in a surgical center." Steven Vold, MD Vold Vision Fayetteville, AR USA | Lawrence Morse, MD, PhD UC Davis Davis, CA USA | | Kishiko Ohkoshi, MD Professor, Director, Chief Vitreoretinal Surgeon St. Luke’s International University Tokyo, Japan | | Julia Schulman, MD NYC Retina New York, NY USA | | Stela Vujosevic, MD Professor, Medial Retina Specialist University Hospital Maggiore della Carita Novara, Italy | | Glenn Yiu, MD, PhD UC Davis Davis, CA USA | | Marco Zarbin, MD, PhD, FACS Rutgers New Jersey Medical School Newark, NJ USA | | MLT Focused "I achieved such good results with MLT that I decided to try MicroPulse for treating retinal diseases. I now use it daily to treat many retinal disorders, and MicroPulse allows me to treat patients who I could not have otherwise." Brandon Philips, MD Carolina Vision Center Fayetteville, NC USA | "MLT is versatile in variety of ways: for patients just starting therapy, replacing an eye drop, as an adjunct to an eye drop or to keep them away from incisional surgery." Nathan Radcliffe, MD New York Eye Surgery Center Bronx, NY USA | "The IQ 577 Laser produces less collateral damage than a traditional green-wavelength laser during the treatment of macular edema. It's more efficient and increases patient comfort for panretinal photocoagulation." Jonathan Walker, MD Lutheran Hospital of Indiana Fort Wayne, IN USA | "The IQ 577 Laser System has simplified and improved the efficiency of laser clinics dramatically." Christopher Riemann, MD Cincinnati Eye Institute Cincinnati, OH USA | "The IQ 577 Laser System with yellow laser is one such promising advancement for the treatment of macular edema." Sviatoslav Suk, MD, PhDEye Microsurgery CenterKiev, Ukraine |
September 11, 2019: MicroPulse® Transscleral Laser Therapy Will be Discussed in Various Presentations and Educational Events at ESCRS 2019 in Paris, France June 3, 2019: Laser treatment for DME: Still a place at the table May 1, 2019: Study shows MicroPulse Laser controls IOP after Keratoplasty April 29, 2019: MicroPulse Laser featured in several Glaucoma and Retina research presentations at Ophthalmic Industry Conferences April 10, 2019: Meet MicroPulse TSCPC Experts at ASCRS in San Diego on May 4-6, 2019 April 8, 2019: ASCRS Breakfast: MicroPulse TSCPC as a Treatment for Failed MIGS Procedures April 1, 2019: The Role of Laser for Retinal Vascular Disease in the Anti-VEGF Era April 1, 2019: MicroPulse featured in multiple abstracts, posters, and presentations at WGC March 1, 2019: How does wavelength factor into choosing a laser? by Caesar Luo, MD January 14, 2019: Subthreshold Laser Treatment for Macular Edema by Matteo Forlini, MD June 25, 2018: IRIDEX Announces Multiple Studies of MicroPulse® Laser Therapy Published at World Ophthalmology Congress May 17, 2018: IRIDEX MicroPulse Technology Featured In Many Scientific Presentations at the European Glaucoma Society Meeting May 02, 2018: IRIDEX Announces Dramatic Increase In MicroPulse Visibility at the 2018 ARVO Meeting September 06, 2017: IRIDEX Explored on Innovations Breakthrough Series
|
|
|
*Bhagat N, Zarbin M, Mansour S, Chong V, and Cardillo JA. Fovea-friendly MicroPulse Laser. Supplement to Retina Today, May/June 2012
|
|
|